Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2095217 Target Snapshot

Fibroblast growth factor receptor · PROTEIN FAMILY · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
279Compounds
115Assays
2Approved Drugs
297.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Fibroblast growth factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P22607. Start with neoplasm, then reuse UniProt P22607 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt P22607 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 11 linked drugs
Open source guide
Disease program
neoplasm

Fibroblast growth factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 11 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BRIVANIB, BRIVANIB ALANINATE, DERAZANTINIB, ENMD-981693. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 11 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fibroblast growth factor receptor as ChEMBL target CHEMBL2095217, mapped to UniProt P22607. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Fibroblast growth factor receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2095217
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22607
Fibroblast growth factor receptor 3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Fibroblast growth factor receptor is the right protein anchor across sources, using UniProt P22607 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as approved-linked support. It currently carries 11 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameFibroblast growth factor receptor
Target TypePROTEIN FAMILY
OrganismHomo sapiens
UniProtP22607
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelFibroblast growth factor receptor 3
UniProt AccessionP22607
Component TypeProtein
Sequence Length806 aa

Fibroblast growth factor receptor 3

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Fibroblast growth factor receptor, mapped to UniProt P22607. ChEMBL maps the protein component as Fibroblast growth factor receptor 3. Sequence length is 806 aa.

Mapped IDP22607
Review nameFibroblast growth factor receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Fibroblast growth factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
neoplasm
11 linked drugs · 11 direct · 11 efficacy
Linked drugBRIVANIB
Linked drugBRIVANIB ALANINATE
Linked drugDERAZANTINIB
Linked drugENMD-981693
Approved-linked Approved
cancer
9 linked drugs · 9 direct · 9 efficacy
Linked drugBRIVANIB
Linked drugBRIVANIB ALANINATE
Linked drugENMD-981693
Linked drugERDAFITINIB
Approved-linked Approved
non-small cell lung carcinoma
7 linked drugs · 7 direct · 7 efficacy
Linked drugENMD-981693
Linked drugERDAFITINIB
Linked drugFEXAGRATINIB
Linked drugFUTIBATINIB
Approved-linked Approved
urinary bladder cancer
4 linked drugs · 4 direct · 4 efficacy
Linked drugERDAFITINIB
Linked drugFEXAGRATINIB
Linked drugINFIGRATINIB
Linked drugROGARATINIB
Approved-linked Approved
urothelial carcinoma
4 linked drugs · 4 direct · 4 efficacy
Linked drugDERAZANTINIB
Linked drugERDAFITINIB
Linked drugFEXAGRATINIB
Linked drugROGARATINIB
Approved-linked Approved
cholangiocarcinoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugFUTIBATINIB
Linked drugINFIGRATINIB
Linked drugINFIGRATINIB PHOSPHATE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BRIVANIB, BRIVANIB ALANINATE, DERAZANTINIB, ENMD-981693. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
2
Phase III
1
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50287.0
KI10.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL190161 9.4 IC50 0.4 Preclinical
CHEMBL191023 9.3 IC50 0.5 Preclinical
CHEMBL191070 9.3 IC50 0.5 Preclinical
CHEMBL339856 9.0 IC50 1.0 Preclinical
CHEMBL189995 9.0 IC50 1.0 Preclinical
CHEMBL373365 9.0 IC50 1.0 Preclinical
CHEMBL192856 8.7 IC50 2.0 Preclinical
CHEMBL363551 8.7 IC50 2.0 Preclinical
CHEMBL1171837 8.66 IC50 2.2 Approved
CHEMBL190389 8.59 IC50 2.6 Preclinical
Distribution

pChEMBL Value Distribution

51
5.0
29
5.5
19
6.0
16
6.5
36
7.0
12
7.5
17
8.0
13
8.5
6
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

PONATINIB
CHEMBL1171837
Approved 2012
Properties Compare Identifier
Assay Landscape

Assay Landscape

115
Total Assays
121
Tested Compounds
2
Assay Types
Binding — 106 assays, 121 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 56 118 6.0
cell-based format 50 3 6.0
Functional — 9 assays, 63 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 6 42 7.9
assay format 3 21 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine